Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences (Nasdaq: CRBU) said company management will participate in investor conferences in November and December 2025.

Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) said company management will participate in investor conferences in November and December 2025.

Scheduled appearances: 2025 Truist Securities BioPharma Symposium, New York — November 6, 2025, and 8th Annual Evercore Healthcare Conference, Coral Gables, FL — December 2, 2025 with a fireside chat at 8:45–9:05 AM ET. Webcasts and event links will be posted on the company Events page and will be available for at least 30 days after each event.

Argus Nov 4 session

-10.70% close to close Open Argus

Details

News Market Reaction – CRBU

In the Nov 4 session, CRBU declined 10.70%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:

• 2025 Truist Securities BioPharma Symposium, New York
  November 6, 2025

• 8th Annual Evercore Healthcare Conference, Coral Gables, FL
  December 2, 2025 with fireside chat at 8:45-9:05 AM ET
  Webcast
  
  

For more information and links to webcasts, please visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies.

Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
media@cariboubio.com
investor.relations@cariboubio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Caribou Biosciences (CRBU) present at the Truist Securities BioPharma Symposium?

Management will participate on November 6, 2025 at the Truist Securities BioPharma Symposium in New York.

What is the date and time of Caribou Biosciences (CRBU) fireside chat at the Evercore Healthcare Conference?

The fireside chat is scheduled for December 2, 2025 from 8:45–9:05 AM ET at the Evercore Healthcare Conference in Coral Gables, FL.

Where can investors watch the Caribou Biosciences (CRBU) conference webcasts?

Webcasts and links will be posted on the company Events page and available on the company website.

How long will Caribou Biosciences (CRBU) webcasts remain available after each investor event?

Webcasts will be available on the company website for at least 30 days after the event.

Will Caribou Biosciences (CRBU) provide a webcast for the Truist and Evercore events?

Yes. The company indicated webcasts and links for both events will be available on its Events page.

How can shareholders find more information about Caribou Biosciences (CRBU) investor events?

Visit the company Events page on its website for schedules, webcasts, and links.